Related content

Receptor radionuclide therapy with ⁹⁰Y-[DOTA]⁰-Tyr³-octreotide (⁹⁰Y-DOTATOC) in neuroendocrine tumours

By Bodei Lisa   Cremonesi Marta   Grana Chiara   Rocca Paola   Bartolomei Mirco   Chinol Marco   Paganelli Giovanni  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 31, Iss. 7, 2004-07 ,pp. : 1038-1046

Springer Publishing Company

Access to resources Recommend Favorite

Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

By Vente M.  

European Radiology, Vol. 19, Iss. 4, 2009-04 ,pp. : 951-959

Springer Publishing Company

Access to resources Recommend Favorite

Pre-therapeutic dosimetry and biodistribution of ⁸⁶Y-DOTA-Phe¹-Tyr³-octreotide versus ¹¹¹In-pentetreotide in patients with advanced neuroendocrine tumours

By Helisch Andreas   Förster Gregor   Reber Helmut   Buchholz Hans-Georg   Arnold Rudolf   Göke Burkhard   Weber Matthias   Wiedenmann Bertram   Pauwels Stanislas   Haus Ulrike   Bouterfa Hakim   Bartenstein Peter  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 31, Iss. 10, 2004-10 ,pp. : 1386-1392

Springer Publishing Company

Access to resources Recommend Favorite

Cautionary note on the use of end-labelling DNA fragments for detection of apoptosis

By Wolvekamp Monique   Darby Ian   Fuller Peter  

Pathology, Vol. 30, Iss. 3, 1998-08 ,pp. : 267-271

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma

By Nakagawa Makoto  

Japanese Journal of Radiology, Vol. 30, Iss. 8, 2012-10 ,pp. : 642-647

Springer Publishing Company

Access to resources Recommend Favorite